Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (6065)	4/1/2002 2:20:14 PM
From: aknahow	Respond to of 52153

Thanks. For a long time have assumed Amevive would be approved. The link to the B of a report on the AAD conference makes me think the FDA will have many questions about Amevive and I now wonder if BGEN will have the answers. apparently the drop out rate in the Amevive trial was unusually high, in both treatment and placebo groups. I could rationalize that because Amevive takes a long time to show results BUT it turns out that, "most of the drop-outs in the treated groups were the best responders." any thoughts on why the best responders would drop out?